Efficacy and safety with long-acting risperidone at medium high doses
✍ Scribed by A. Chinchilla Moreno; M. Vega Piñero; M.D. Crespo Hervás
- Book ID
- 118438148
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- French
- Weight
- 43 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0924-9338
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot a
## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi